tiprankstipranks
Advertisement
Advertisement

DE:F6T Stock Latest News

Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
RatingsMaintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
25d ago
FATE
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
PremiumThe Fly
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
26d ago
FATE
Fate Therapeutics presents updated Phase 1 data of FT819
PremiumThe Fly
Fate Therapeutics presents updated Phase 1 data of FT819
4M ago
FATE
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
PremiumCompany Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
4M ago
FATE
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
PremiumCompany Announcements
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
4M ago
FATE
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
PremiumRatingsFate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
4M ago
FATE
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
Premium
The Fly
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
4M ago
FATE
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
5M ago
FATE
Is FATE a Buy, Before Earnings?
PremiumPre-Earnings
Is FATE a Buy, Before Earnings?
5M ago
FATE
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
PremiumThe Fly
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
5M ago
FATE
Fate Therapeutics Reports Promising Phase 1 Trial Results
PremiumCompany Announcements
Fate Therapeutics Reports Promising Phase 1 Trial Results
5M ago
8K
FATE
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
PremiumThe Fly
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
5M ago
FATE
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
PremiumRatingsHold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
5M ago
FATE
Fate Therapeutics Appoints New CFO Kamal Adawi
Premium
Company Announcements
Fate Therapeutics Appoints New CFO Kamal Adawi
5M ago
8K
FATE
Fate Therapeutics appoints Adawi as CFO
Premium
The Fly
Fate Therapeutics appoints Adawi as CFO
5M ago
FATE
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
PremiumCompany Announcements
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
7M ago
FATE
Fate Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Fate Therapeutics Reports Q2 2025 Financial Results
7M ago
FATE
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
PremiumThe Fly
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
7M ago
FATE
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
PremiumRatings
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
7M ago
FATE
Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials
PremiumRatingsCautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials
7M ago
FATE
Fate Therapeutics Announces Corporate Restructuring Plan
Premium
Company Announcements
Fate Therapeutics Announces Corporate Restructuring Plan
7M ago
8K
FATE
Fate Therapeutics reports Q2 EPS (29c), consensus (34c)
Premium
The Fly
Fate Therapeutics reports Q2 EPS (29c), consensus (34c)
7M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >